

Masahiro Sakagami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3059575/publications.pdf>

Version: 2024-02-01

28
papers

1,269
citations

471061

17
h-index

552369

26
g-index

28
all docs

28
docs citations

28
times ranked

1606
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 1030-1060.	6.6	294
2	The Particle has Landed”Characterizing the Fate of Inhaled Pharmaceuticals. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, S-71-S-87.	0.7	191
3	Development and characterization of a naturally derived lung extracellular matrix hydrogel. <i>Journal of Biomedical Materials Research - Part A</i> , 2016, 104, 1922-1935.	2.1	121
4	In Vitro Aqueous Fluid-Capacity-Limited Dissolution Testing of Respirable Aerosol Drug Particles Generated from Inhaler Products. <i>Pharmaceutical Research</i> , 2010, 27, 786-795.	1.7	71
5	Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. <i>Journal of Controlled Release</i> , 2002, 80, 207-218.	4.8	69
6	Iloprost reverses established fibrosis in experimental right ventricular failure. <i>European Respiratory Journal</i> , 2015, 45, 449-462.	3.1	68
7	Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. <i>Journal of Controlled Release</i> , 2001, 77, 117-129.	4.8	64
8	Expression and Transport Functionality of FcRn within Rat Alveolar Epithelium: A Study in Primary Cell Culture and in the Isolated Perfused Lung. <i>Pharmaceutical Research</i> , 2006, 23, 270-279.	1.7	61
9	Insulin Disposition in the Lung Following Oral Inhalation in Humans. <i>Clinical Pharmacokinetics</i> , 2004, 43, 539-552.	1.6	43
10	In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs. <i>Advanced Drug Delivery Reviews</i> , 2020, 161-162, 63-74.	6.6	38
11	The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 25, 369-378.	1.9	36
12	Novel low molecular weight lignins as potential anti-emphysema agents: In vitro triple inhibitory activity against elastase, oxidation and inflammation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 296-304.	1.1	32
13	Respirable Microspheres for Inhalation. <i>Clinical Pharmacokinetics</i> , 2005, 44, 263-277.	1.6	30
14	Solute disposition in the rat lung in vivo and in vitro: Determining regional absorption kinetics in the presence of mucociliary escalator. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 594-604.	1.6	27
15	Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: Effects of temperature and metabolic inhibitors. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1958-1968.	1.6	20
16	Fractional contribution of lung, nasal and gastrointestinal absorption to the systemic level following nose-only aerosol exposure in rats: a case study of 3.7-µm fluorescein aerosols. <i>Archives of Toxicology</i> , 2003, 77, 321-329.	1.9	18
17	Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption. <i>Therapeutic Delivery</i> , 2013, 4, 1511-1525.	1.2	18
18	Insulin Self-association: Effects on Lung Disposition Kinetics in the Airways of the Isolated Perfused Rat Lung (IPRL). <i>Pharmaceutical Research</i> , 2007, 24, 1636-1644.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Sulfated Caffeic Acid Dehydropolymer Attenuates Elastase and Cigarette Smoke Extract-induced Emphysema in Rats: Sustained Activity and a Need of Pulmonary Delivery. <i>Lung</i> , 2014, 192, 481-492.	1.4	10
20	In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products. <i>Pharmaceutical Research</i> , 2019, 36, 95.	1.7	10
21	Sulfated dehydropolymer of caffeic acid: In vitro anti-lung cell death activity and in vivo intervention in emphysema induced by VEGF receptor blockade. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 181-190.	1.1	9
22	Salvianolic acid B as an anti-emphysema agent I: In vitro stimulation of lung cell proliferation and migration, and protection against lung cell death, and in vivo lung STAT3 activation and VEGF elevation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 53, 107-115.	1.1	8
23	Targeted Drug Delivery Through the Respiratory System: Molecular Control on Lung Absorption and Disposition. , 2011, , 127-141.		4
24	In vitro lung epithelial cell transport and anti-interleukin-8 releasing activity of liposomal ciprofloxacin. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 68-76.	1.9	4
25	Salvianolic acid B as an anti-emphysema agent II: In vivo reversal activities in two rat models of emphysema. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 53, 52-60.	1.1	4
26	Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model. <i>Biopharmaceutics and Drug Disposition</i> , 2020, 41, 32-43.	1.1	3
27	Pulmonary delivery of anorectic oxyntomodulin in rats: food intake suppression, reduced body weight gain and pharmacokinetics. <i>Therapeutic Delivery</i> , 2015, 6, 297-306.	1.2	2
28	The Lung Structure Maintenance Program: Sustaining Lung Structure during Adulthood and Implications for COPD Risk. , 0, , 303-310.		0